LobbyingTufts Medicine lobbying by quarter
Tufts Medicine's latest lobbying report covers Q2 2026, at $60K. The four quarters Q3 2025–Q2 2026 total $240K. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Tufts Medicine
- Latest quarter
- $60K
- Q2 2026 · 1 reports
- Last 12 months
- $240K
- Last 4 quarters
- vs last quarter
- 0.0%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $60K | 1 |
| Q1 2023 | $50K | 1 |
| Q2 2023 | $50K | 1 |
| Q3 2023 | $50K | 1 |
| Q4 2023 | $60K | 1 |
| Q1 2024 | $60K | 1 |
| Q2 2024 | $60K | 1 |
| Q3 2024 | $60K | 1 |
| Q4 2024 | $60K | 1 |
| Q1 2025 | $60K | 1 |
| Q2 2025 | $60K | 1 |
| Q3 2025 | $60K | 1 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $60K | 1 |
Policy issues the reports name
- Health issues15 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Health & Human Services, Dept of (HHS)3 reports
Firms it paid
| Firm | ||
|---|---|---|
| Ernst & Young | $870K | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Ernst & Young | $60K |
| 04/20for Q1 | Ernst & Young | $60K |
| 01/19for Q4 2025 | Ernst & Young | $60K |
| 25/10/19for Q3 2025 | Ernst & Young | $60K |
| 25/07/21for Q2 2025 | Ernst & Young | $60K |
| 25/04/21for Q1 2025 | Ernst & Young | $60K |
| 25/01/20for Q4 2024 | Ernst & Young | $60K |
| 24/10/21for Q3 2024 | Ernst & Young | $60K |
| 24/07/22for Q2 2024 | Ernst & Young | $60K |
| 24/04/22for Q1 2024 | Ernst & Young | $60K |
| 24/01/22for Q4 2023 | Ernst & Young | $60K |
| 23/10/20for Q3 2023 | Ernst & Young | $50K |
| 23/07/20for Q2 2023 | Ernst & Young | $50K |
| 23/04/20for Q1 2023 | Ernst & Young | $50K |
| 23/01/20for Q4 2022 | Ernst & Young | $60K |